Evaluation of Dose-Dependent Repeated-Dose Neramexane Effects on Cardiac Repolarisation (QT/QTc Interval Duration): Electrocardiogram (ECG) Study in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

126

Participants

Timeline

Start Date

September 30, 2009

Primary Completion Date

April 30, 2010

Study Completion Date

April 30, 2010

Conditions

Healthy Subjects

Interventions

DRUG

Neramexane

"Dosage form:~25 mg immediate release \[IR\] tablets (=15.9 mg neramexane free base)~37.5 mg IR tablets (=23.9 mg neramexane free base)"

Trial Locations (1)

Parexel International GmbH, Berlin